ABBV vs PANW: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Palo Alto Networks, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Palo Alto Networks, Inc. · Technology
$287.78
+2.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
PANW has more upside to fair value
(+2.9%).
ABBV trades at a lower forward P/E
(128.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PANW |
| Current Price |
$261.07 |
$287.78 |
| Fair Value Estimate |
$264.30 |
$296.19 |
| Upside to Fair Value |
+1.2%
|
+2.9%
|
| Market Cap |
$461.3B |
$196.1B |
| Forward P/E |
128.0x
|
248.9x
|
| EV / EBITDA |
31.0x
|
85.9x
|
| Price / Sales |
7.3x
|
18.5x
|
| Price / FCF |
22.1x
|
45.7x
|
| Revenue Growth YoY |
+12.4%
|
+31.1%
|
| Gross Margin |
70.7%
|
71.9%
|
| Operating Margin |
27.6%
|
9.6%
|
| Return on Equity |
68.0%
|
6.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
2.19%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Palo Alto Networks is a leading cybersecurity company specializing in next-generation security platforms with a strong subscription and support revenue base comprising approximately 81% of total revenue. The company benefits from a wide and expanding competitive moat driven by its AI- and platform-driven cybersecurity solutions, led by a seasoned management team. Despite strong revenue growth of …
Accumulation Zones
| Metric |
ABBV |
PANW |
| Zone Low |
$198.23 |
$222.14 |
| Zone High |
$224.66 |
$251.76 |
| In Buy Zone? |
No
|
No
|